Module 4: Regulatory Strategy for a New Active Substance: Global Clinical Development

22nd – 24th January 2020

De Vere Latimer Estate, Church Lane, HP5 1UG Chesham, UK

Module Leader(s): **Nicole Herijgers**

Date: Wednesday 22nd January

Time	Activity	Speaker
15.30	Registration	
16.00 – 16.10	Welcome & Introduction to Module	Module Leader Nicole Herjigers Janssen Biologics
16.10 – 17.00	**Lecture 1: Strategy for a Global Development** What is global? Costs: development, healthcare, pharmaceuticals Territories used in development Design of a CT program Product profile Into full development	Ian Braithwaite INC Research
17.00 – 18.00	**Lecture 2: The Clinical Trial Programme** Setting the clinical strategy Target product profiles Selection of clinical endpoints and comparators Impact on the product label Issues in Global Development	Ewoud-Jan van Hoogdalem PRA Health Sciences
18.00	New Student Tutorial	Dr Laura Brown Course Director
19.30	**Dinner**	

Module 4: Regulatory Strategy for a New Active Substance: Global Clinical Development

22nd – 24th January 2020

Date: Thursday 23rd January

Time	Activity	Speaker
08.25 – 08.30	Chairpersons Introduction	
08.30 – 09.30	**Lecture 3: Overview of Requirements for Clinical Trials** Phases of clinical development **Toxicology package requirements for each phase of development** Standard Trial designs Brief overview of CTA procedures (include experiences of VHP) Impact of proposed changes to EU Clinical trial directive Data requirements for clinical study start-up Quality Assurance systems in clinical trials Insurance and indemnity Ethics committee approvals Import/export and Labelling of experimental substances	Liesbeth Hof Propharma Group
09.30 – 10.15	**Lecture 4: Ethnic Factors and Clinical Strategies for Non-ICH Markets** Defining the strategy Understanding the data requirements Analysing and presenting the data	TO BE CONFIRMED
10.15 – 10.45	**Refreshment Break**	
10.45 – 11.45	**Lecture 5: The Statistical Input** Designing and analysing clinical trials Regulatory requirements Key principles - bias / precision / multiplicity Maximising reliability of conclusions How many patients do we need? Statistical input to protocol	Thomas Zwingers CROS-NT
11.45 – 12.30	**Lecture 6 : Paediatrics and other Special Populations** The need for paediatric medicines Paediatric regulations and incentive systems Design and issues in paediatric clinical development Geriatric Studies Other special populations (renal/hepatic studies, drug:drug interaction studies)	Amy Cheung AstraZeneca
12.30 – 13.30	**Lunch**	

13.30 – 14.15	**Lecture 7: Unconventional Study Designs** Combined Phase studies (eg Phase I/II or Phase II/III trials) Phase 0 studies Early stopping rules Multi-arm studies Adaptive design Phase IV studies	Bob Clay Highbury Regulatory Science
14.15 – 15.00	**Lecture 8: Philosophies and Assessment Techniques of the Regulatory Authorities** FDA vs EU vs others Consequences of review philosophy Regulatory developments - accelerated approvals, priority reviews, interaction with regulators, regulatory reform	Graham Higson
15.00 – 15.30	**Refreshment Break**	
15.30 – 17.00	**Case Study and feedback**	
17.00 – 18.00	**Lecture 9: Pharmacoeconomics Studies** What needs to be done? How do we include measures of pharmacoeconomics in clinical trials? When do we do them?	
19.00	**Dinner**	

Module 4: Regulatory Strategy for a New Active Substance: Global Clinical Development

22nd – 24th January 2020

Date: Friday 24th January

08.25 – 08.30	Chairperson's Introduction	
08.30 – 09.15	**Lecture 10: Clinical Study Reports – Strategic Importance** Purpose The ICH guideline Use of in international dossiers Study reports for special situations Planning and preparation	Julia Forjanic Kapproth Trilogy
09.15 – 10.00	**Lecture 11: Clinical Summary Documentation** When are the clinical summary documents needed? Content and style Assessment of benefits and risks Regional considerations Success and Failure Updates	Nicole Herijgers Janssen Biologics
10.00 – 10.30	**Refreshment Break**	
10.30 – 11.15	**Lecture 12: Pharmacovigilance Strategies** Trends in Pharmacovigilance legislation Impact of new EU Pharmacovigilance legislation PSURs and PBRERs (include moving from DSURs to PSURs and PBRERs) Risk Management Systems Monitoring effectiveness of Risk Management Strategies	Lambert Creuwels Lundbeck
11.15 – 13.00	Case Study and presentations	
13.00 – 14.00	**Lunch**	
14.00 – 14.45	**Lecture 13: Pharmacogenetics/Pharmacogenomics** Strategic value of Pharmacogenomics Better and safer drugs Disease screening Impact on drug discovery and approval Barriers to pharmacogenomics progress	Simon Smith AstraZeneca
14.45 – 15.45	**Lecture 14: Common Faults in Clinical Registration Packages** **An agency view of clinical documentation**	MHRA Speaker
15.45	**Close of Module**	